Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access
Executive Summary
How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.